-
公开(公告)号：US20060270874A1
公开(公告)日：2006-11-30
申请号：US11414042
申请日：2006-04-28
申请人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Matthias Koerner , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Timothy Woodcock
发明人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Matthias Koerner , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Timothy Woodcock
IPC分类号： C07C311/45
CPC分类号： C07C311/51
摘要： The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋物，上述化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在 控制或预防癌症等疾病。
-
公开(公告)号：US07208526B2
公开(公告)日：2007-04-24
申请号：US11414042
申请日：2006-04-28
申请人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Matthias Koerner , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Timothy Woodcock
发明人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Matthias Koerner , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Timothy Woodcock
IPC分类号： A61K31/18 , C07C311/51
CPC分类号： C07C311/51
摘要： The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在 控制或预防癌症等疾病。
-
公开(公告)号：US20070010564A1
公开(公告)日：2007-01-11
申请号：US11477641
申请日：2006-06-29
申请人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt , Timothy Woodcock
发明人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt , Timothy Woodcock
IPC分类号： A61K31/44 , A61K31/381 , C07D333/22 , C07D213/56
CPC分类号： A61K31/38 , A61K31/381 , A61K31/44 , C07D213/59 , C07D333/24
摘要： The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
-
4.发明授权公开(公告)号：US07208506B2
公开(公告)日：2007-04-24
申请号：US11477641
申请日：2006-06-29
申请人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt , Timothy Woodcock
发明人： Edward Boyd , Frederick Brookfield , Jonathan Gridley , Manfred Kubbies , Raymond Lau , Ulrike Reiff , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt , Timothy Woodcock
IPC分类号： A61K31/38 , A61K31/42 , A61K31/425 , A61K31/44
CPC分类号： A61K31/38 , A61K31/381 , A61K31/44 , C07D213/59 , C07D333/24
摘要： The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物，其中R 1，R 2和R 3 3定义为其药学上可接受的盐，对映体形式 ，非对映异构体和外消旋物，上述化合物的制备，含有它们的药物及其制备，以及上述化合物在控制或预防诸如癌症等疾病中的用途。
-
公开(公告)号：US20070123513A1
公开(公告)日：2007-05-31
申请号：US11594297
申请日：2006-11-08
申请人： Lothar Kling , Ulrike Reiff , Manfred Schwaiger , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt
发明人： Lothar Kling , Ulrike Reiff , Manfred Schwaiger , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt
IPC分类号： A61K31/55 , A61K31/4439 , A61K31/4412 , A61K31/4545 , C07D213/63
CPC分类号： C07D213/71
摘要： The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物：其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，这些化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在控制或预防中的用途 的疾病，如癌症。
-
公开(公告)号：US07625896B2
公开(公告)日：2009-12-01
申请号：US11594297
申请日：2006-11-08
申请人： Lothar Kling , Ulrike Reiff , Manfred Schwaiger , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt
发明人： Lothar Kling , Ulrike Reiff , Manfred Schwaiger , Georg Tiefenthaler , Wolfgang von der Saal , Thomas von Hirschheydt
IPC分类号： A61K31/535 , C07D413/00 , A61K31/445 , C07D211/68 , C07D401/00 , A61K31/44
CPC分类号： C07D213/71
摘要： The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物：其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，这些化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在控制或预防中的用途 的疾病，如癌症。
-
公开(公告)号：US20090311725A1
公开(公告)日：2009-12-17
申请号：US12299918
申请日：2007-05-15
CPC分类号： C12N15/85 , C07K16/00 , C07K16/065 , C07K2319/03
摘要： The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
摘要翻译： 本发明描述了包含在5'至3'方向的核酸a）编码不具有帧内终止密码子的异源多肽的第一核酸，b）以5'剪接供体位点开始并以 3''剪接受体位点，其包含内部翻译终止密码子和多聚腺苷酸化信号，以及c）编码i）至少跨膜结构域片段的核酸，或ii）GPI锚的信号肽。
-
![Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives](/abs-image/US/2006/08/15/US07091345B2/abs.jpg.150x150.jpg)
公开(公告)号：US07091345B2
公开(公告)日：2006-08-15
申请号：US10697543
申请日：2003-10-30
申请人： Jianping Cai , Nikolaos Dimoudis , Konrad Honold , Kin-Chun Luk , Stefan Scheiblich , Hilke Sudergat , Georg Tiefenthaler , Oliver Tonn
发明人： Jianping Cai , Nikolaos Dimoudis , Konrad Honold , Kin-Chun Luk , Stefan Scheiblich , Hilke Sudergat , Georg Tiefenthaler , Oliver Tonn
IPC分类号： C07D471/04 , C07D491/113 , A61K31/519
CPC分类号： C07D487/04 , C07D491/10
摘要： Compounds of formula I are described. These compounds are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases. Thus, these compounds are useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer. Also described are methods of making and using compounds of formula I as well as pharmaceutical compositions containing these compounds.
摘要翻译： 描述式I化合物。 这些化合物是蛋白激酶抑制剂，特别是它们抑制src家族酪氨酸激酶。 因此，这些化合物可用于治疗由src酪氨酸激酶介导的疾病，包括细胞增殖性疾病如癌症。 还描述了制备和使用式I化合物的方法以及含有这些化合物的药物组合物。
-
9.发明授权Amphotropic retrovirus packaging cell line, process for its production and use thereof 有权大片逆转录病毒包装细胞系，其生产和使用过程公开(公告)号：US06475786B1
公开(公告)日：2002-11-05
申请号：US09700979
申请日：2001-06-11
IPC分类号： C12N500
CPC分类号： C12N7/00 , C12N15/86 , C12N2740/13052
摘要： A titer of retroviral vectors of at least about 107 colony-forming units/ml cell culture supernatants is obtained using an amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes.
摘要翻译： 使用包含功能性gag，pol和env基因整合到基因组中的功能性gag，pol和env基因，获得至少约107个菌落形成单位/ ml细胞培养上清的逆转录病毒载体的滴度，其中基因gag和 pol独立于env基因的表达调节，其中所述细胞系的基因组含有一个或两个功能活性的env基因。
-
公开(公告)号：US08354516B2
公开(公告)日：2013-01-15
申请号：US12299918
申请日：2007-05-15
CPC分类号： C12N15/85 , C07K16/00 , C07K16/065 , C07K2319/03
摘要： The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
摘要翻译： 本发明描述了包含在5'至3'方向的核酸a）编码不具有帧内终止密码子的异源多肽的第一核酸，b）以5'剪接供体位点开始并以 3''剪接受体位点，其包含内部翻译终止密码子和多聚腺苷酸化信号，以及c）编码i）至少跨膜结构域片段的核酸，或ii）GPI锚的信号肽。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.04 秒)
